Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.

27 Apr 2010

International Day for Fighting Infection focuses on hospital infection control

Hospital acquired infections are the focus for the 3rd International Day for Fighting Infection, being marked on St. George’s Day, as experts meet to look at the evolution of infection control in hospitals.

22 Apr 2010

MRSA infections on the rise in hospitals and health care settings: AHRQ report

Despite activities to identify and reduce the spread of methicillin-resistant Staphylococcus aureus (MRSA) and other health care-associated infections in hospitals and health care settings nationwide, new reports released by the Agency for Healthcare Research and Quality show that MRSA is on the rise and continues to pose an alarming threat.

22 Apr 2010

New study quantifies prevalence of MRSA infections in different patient populations

A multi-center study led by a researcher at Rhode Island Hospital has determined that long-term elder care, HIV-infected and hemodialysis patients are at increased risk of carrying methicillin-resistant Staphylococcus aureus (MRSA) in their nose.

21 Apr 2010

Forest Laboratories' fourth-quarter net sales up 11.0% to $995.6M

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.07 in the fourth quarter of fiscal 2010.

21 Apr 2010

New in vitro study results of Hydrofiber dressing to be presented at SAWC/WHS 2010

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results in which a Hydrofiber dressing containing ionic silver was observed to conform more closely to a porcine tissue surface in a shallow wound model than did certain silver-containing foam dressings following hydration.

19 Apr 2010

Flavonoids of onion are natural alternative to artificial additives in food industry: Study

Some components of the onion have antioxidant and antimicrobial properties, making it possible to use this bulb for food preservation. This is demonstrated by researchers from the Polytechnic University of Catalu-a and the University of Barcelona in a study that has just been published in the International Journal of Food Science and Technology.

16 Apr 2010

Rib-X Pharmaceuticals to present delafloxacin Phase 2 study data at 20th ECCMID

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced that an oral presentation of data for delafloxacin, its lead antibiotic candidate, will be given at the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 10-14, in Vienna, Austria by Paul G. Ambrose, Pharm.D, FIDSA, Director, Institute for Clinical Pharmacodynamics, Ordway Research Institute.

12 Apr 2010

Phase I study of Affinium Pharmaceuticals' AFN-1252 for MRSA initiated

Affinium Pharmaceuticals announced today the commencement of a Phase I study in the United States for its novel molecular entity, AFN-1252, a first in class antibiotic candidate focused on the oral and IV treatment of susceptible and highly resistant strains of Staphylococcus aureus.

12 Apr 2010

Scientists identify specific mechanism that triggers resistance to vancomycin

A new study led by the scientific director of the Michael G. DeGroote Institute for Infectious Disease Research has uncovered for the first time how bacteria recognize and develop resistance to a powerful antibiotic used to treat superbug infections.

12 Apr 2010

Medtronic named 2010 MDEA winner for excellence in medical device design

Medtronic announced today that the company was named a 2010 Medical Device Excellence Award winner for excellence in medical device design for its Hydrodebrider System, manufactured by the company's Ear Nose and Throat business unit.

9 Apr 2010

Effective compound against antibiotic-resistant biofilms

Researchers at North Carolina State University have found a chemical compound that, when used in conjunction with conventional antibiotics, is effective in destroying biofilms produced by antibiotic-resistant strains of bacteria such as the Staphylococcus strain MRSA and Acinetobacter. The compound also re-sentsitizes those bacteria to antibiotics.

9 Apr 2010

Superbugs on the decline in Scottish hospitals

The number of cases of hospital infections is on the decline in Scotland. Clostridium difficile, the hospital super bug which brings down a number of patients each year have halved in the last year. In the last 3 months of last year the patients over 65 years reported 672 cases of Clostridium difficile. This is a 48% decline from the 1,299 cases reported in the last three months of 2008.

9 Apr 2010

Cempra Pharmaceuticals announces schedule of poster presentations at ECCMID 2010

Cempra Pharmaceuticals today announced its schedule of poster presentations at the 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, on April 10-13, 2010.

8 Apr 2010

Cepheid to launch GeneXpert Infinity-48 in Europe at 20th ECCMID

Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.

7 Apr 2010

Mtb fine-tunes behaviour to escape detection and causes TB

Mycobacterium tuberculosis (Mtb) possesses extraordinary survival ability by masking itself from the host immune system and persisting for decades inside the host. Speaking at the Society for General Microbiology's spring meeting in Edinburgh today, Dr Kristine Arnvig provides further insight into how the bacterium causes tuberculosis (TB) by fine-tuning its behaviour in response to its surroundings to escape detection.

1 Apr 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.

31 Mar 2010

Trius Therapeutics' Phase 1 trial establishes safety and tolerability of IV torezolid phosphate for MRSA

Trius Therapeutics, Inc. today announced results from its Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of the intravenous (IV) dosage form of torezolid phosphate, an IV and orally administered second generation oxazolidinone for the treatment of serious gram positive infections, including methicillin-resistant Staphylococcus aureus (MRSA).

30 Mar 2010

CA-MRSA becoming common among children admitted to PICU's

Once considered a hospital anomaly, community-acquired infections with drug-resistant strains of the bacterium Staphylococcus aureus now turn up regularly among children hospitalized in the intensive-care unit, according to research from the Johns Hopkins Children's Center.

26 Mar 2010